Trial for lupus kidney inflammation using LNP023
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lab-confirmed lupus activity: a positive ANA and/or positive anti–double-stranded DNA (anti-dsDNA) test
- Your kidney disease has been proven by recent biopsy within 3 months, showing lupus nephritis class III or IV (sometimes with class V)
- Your kidney inflammation is active now and your doctors plan to start or start/re-start steroid treatment plus mycophenolate (MMF) or mycophenolic acid (MPS)
- Your kidney function is enough for the trial: eGFR is 30 or higher
- This is your first lupus nephritis episode or a flare (new onset or flare, not a long-standing stable case)
- You must be on stable background care like anti-malarials (if you can take them) and kidney-protecting medicines (ACE inhibitor/ARB) at a stable dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
This trial tests a new medicine called SIM0278 for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the drug can help control the disease and improve kidney health.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.